Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Group 1 - Fulcrum Therapeutics, Inc. (FULC) has experienced significant selling pressure, resulting in a 65.6% loss over the past four weeks, but it is now considered to be in oversold territory [1] - Wall Street analysts anticipate that FULC will report better earnings than previously predicted, with a consensus EPS estimate increase of 24.8% over the last 30 days [3] - The stock's Relative Strength Index (RSI) is currently at 20.49, indicating a potential trend reversal as the heavy selling appears to be exhausting itself [3] Group 2 - FULC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a strong potential for price appreciation [3]